Bicocca Open Archive

Logo unimib boa
COLOMBO, NICOLETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 21.411
EU - Europa 7.328
AS - Asia 4.001
SA - Sud America 43
Continente sconosciuto - Info sul continente non disponibili 27
OC - Oceania 24
AF - Africa 16
Totale 32.850
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.039
IE - Irlanda 1.373
CN - Cina 1.327
IT - Italia 1.296
SG - Singapore 1.252
RU - Federazione Russa 1.021
UA - Ucraina 990
SE - Svezia 953
HK - Hong Kong 838
GB - Regno Unito 433
DE - Germania 422
CA - Canada 359
FI - Finlandia 283
VN - Vietnam 174
AT - Austria 143
FR - Francia 143
IN - India 92
NL - Olanda 88
TR - Turchia 83
ID - Indonesia 78
JP - Giappone 72
DK - Danimarca 55
ES - Italia 24
BE - Belgio 23
BR - Brasile 22
AU - Australia 20
EU - Europa 20
TW - Taiwan 18
KR - Corea 17
IR - Iran 16
RO - Romania 15
CL - Cile 13
MX - Messico 13
GR - Grecia 8
PL - Polonia 8
A2 - ???statistics.table.value.countryCode.A2??? 7
CZ - Repubblica Ceca 7
NO - Norvegia 6
PK - Pakistan 6
CH - Svizzera 5
MD - Moldavia 5
MK - Macedonia 5
PT - Portogallo 5
BG - Bulgaria 4
MA - Marocco 4
RS - Serbia 4
ZA - Sudafrica 4
KZ - Kazakistan 3
MU - Mauritius 3
NZ - Nuova Zelanda 3
PH - Filippine 3
QA - Qatar 3
AL - Albania 2
BD - Bangladesh 2
HR - Croazia 2
IL - Israele 2
LB - Libano 2
LK - Sri Lanka 2
MY - Malesia 2
PE - Perù 2
TH - Thailandia 2
UY - Uruguay 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BY - Bielorussia 1
CO - Colombia 1
EG - Egitto 1
FK - Isole Falkland (Malvinas) 1
GH - Ghana 1
GI - Gibilterra 1
HU - Ungheria 1
KG - Kirghizistan 1
MN - Mongolia 1
MT - Malta 1
NG - Nigeria 1
NP - Nepal 1
PF - Polinesia Francese 1
SA - Arabia Saudita 1
SC - Seychelles 1
UG - Uganda 1
Totale 32.850
Salva come PNG Salva come JPEG
Città #
Ann Arbor 3.337
Woodbridge 2.684
Fairfield 2.357
Houston 1.888
Dublin 1.293
Jacksonville 1.191
Singapore 1.060
Ashburn 1.031
Wilmington 1.007
Seattle 873
Hong Kong 822
Cambridge 787
Dearborn 736
Chandler 695
Princeton 639
New York 590
Milan 348
Lawrence 315
Altamura 290
Nanjing 278
Frankfurt am Main 268
Santa Clara 256
Lachine 202
Beijing 191
San Diego 143
Vienna 143
Andover 125
Boardman 103
Shanghai 102
Guangzhou 98
Dong Ket 96
Nanchang 85
Toronto 85
London 83
Jakarta 74
Falls Church 69
Shenyang 69
Rome 62
Hebei 60
Helsinki 59
Tianjin 55
Ottawa 53
Norwalk 51
Mountain View 49
Changsha 46
Chicago 42
Jiaxing 42
Redmond 41
Hangzhou 39
Huizen 38
Los Angeles 35
Jinan 29
Kunming 26
Fremont 25
University Park 25
Zhengzhou 23
Pune 22
Tokyo 21
Lappeenranta 19
Brussels 17
Gaithersburg 17
Ningbo 17
Detroit 15
San Mateo 15
Turin 15
Hefei 14
Hyderabad 14
Hanoi 13
Lissone 13
Taipei 13
Washington 12
Hounslow 11
Kilburn 11
São Paulo 11
Amsterdam 10
Chengdu 10
Dallas 10
Groningen 10
Phoenix 10
Sacramento 9
Auburn Hills 8
Edmonton 8
Florence 8
Melbourne 8
Panvel 8
Taizhou 8
Bologna 7
Carate Brianza 7
Genova 7
Kiev 7
Montréal 7
Munich 7
Naples 7
Palermo 7
Perugia 7
San Jose 7
Snodland 7
Assago 6
Central 6
Desio 6
Totale 25.685
Salva come PNG Salva come JPEG
Nome #
High-dose epirubicin in patients with advanced or recurrent uterine sarcoma 481
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer 250
Pre-operative evaluation of epithelial ovarian cancer patients: Role of whole body diffusion weighted imaging MR and CT scans in the selection of patients suitable for primary debulking surgery. A single-centre study 203
ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease 202
Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer 197
Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers 195
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer 190
CD73 Regulates Stemness and Epithelial-Mesenchymal Transition in Ovarian Cancer-Initiating Cells 180
Erratum: Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Annals of Oncology (2017) 28 (iv72-iv83) DOI: 10.1093/annonc/mdx220) 179
ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease 178
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12 168
Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer 167
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 167
Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial 162
Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series 161
Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation 157
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial 156
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale 155
Lack of activity of cyclophosphamide in ovarian cancer patients refractory to cis-dichlorodiammine platinum 155
Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer 154
Effect of a streptococcal preparation (OK432) on natural killer activity of tumour-associated lymphoid cells in human ovarian carcinoma and on lysis of fresh ovarian tumour cells 151
Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trial 149
Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study 148
Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: A phase III trial of the AGO OVAR, COGI, GINECO, and GEICO-the MIMOSA study 148
Diffusion-weighted MR imaging in assessing cervical tumour response to nonsurgical therapy 147
Reply to M.L. Friedlander et al 147
The disposition of carboplatin in ovarian cancer patients 146
Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale 144
Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer 143
A reassessment of the role of second-look laparotomy in advanced ovarian cancer 143
Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients 143
Low-dose oral etoposide in epithelial cancer of the ovary 143
Platinum-based neoadjuvant chemotherapy followed by radical surgery for cervical carcinoma international federation of gynecology and obstetrics stage IB2-IIB 143
DR antigen expression on ovarian carcinoma cells does not correlate with their capacity to elicit an autologous proliferative response 142
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 142
Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge 142
Peripheral neurotoxicity of taxol in patients previously treated with cisplatin 141
Chemo-conization in early cervical cancer 140
Neoadjuvant chemotherapy in cervical cancer: An update 140
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial 140
The role of surgery in gestational trophoblastic disease 139
Long-term follow-up of patients with an isolated ovarian recurrence after conservative treatment of epithelial ovarian cancer: review of the results of an international multicenter study comprising 545 patients 139
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial 139
Trabectedin as single agent in relapsed advanced ovarian cancer: Results from a retrospective pooled analysis of three phase II trials 138
Risk-reducing salpingo-oophorectomy in women at higher risk of ovarian and breast cancer: A single institution prospective series 138
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase III trial of the gynecologic cancer intergroup 137
Tumor-derived chemotactic factor(s) from human ovarian carcinoma: evidence for a role in the regulation of macrophage content of neoplastic tissues 137
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives 137
Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cells 136
A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups 136
FORWARD I: A Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer 135
Outcome according to residual disease (surgeon's report vs pre-chemotherapy imaging) in patients with bevacizumab-treated ovarian cancer: Analysis of the ROSiA study 135
Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy 134
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion 134
Treatment of advanced ovarian cancer (OC): A randomized trial comparing different platinum (P) combinations 134
Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: Results of a randomized, double-blind, phase 2, parallel-arm study 134
Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis 134
Antibody-dependent and -independent cytotoxicity of human mononuclear phagocytes: defective stimulation of tumoricidal activity in milk macrophages 133
BRCA1/2 molecular assay for ovarian cancer patients: A survey through Italian departments of oncology and molecular and genomic diagnostic laboratories 132
Aggressive angiomyxoma of the vulva 131
Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 131
Methotrexate with citrovorum factor in low-risk gestational trophoblastic tumor 131
Cisplatin, vinblastine, and bleomycin combination chemotherapy in metastatic granulosa cell tumor of the ovary 131
Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status 130
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens 130
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial 130
Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer 129
Ultrasonographic diagnosis and longitudinal follow-up of recurrences after conservative surgery for borderline ovarian tumors 129
Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives 129
Robotic Surgery: Changing the Surgical Approach for Endometrial Cancer in a Referral Cancer Center 128
Adult primary cervical rhabdomyosarcomas: A Multicentric cross-national case series 128
Surgical management of malignant ovarian germ-cell tumors: 10 years' experience of 129 patients 127
Neoadjuvant chemotherapy prior to pelvic exenteration in patients with recurrent cervical cancer: Single institution experience 127
Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients 127
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer 127
Early oral versus "traditional" postoperative feeding in gynecologic oncology patients undergoing intestinal resection: A randomized controlled trial 126
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer 126
Pure ovarian immature teratoma, a unique and curable disease: 10 years' experience of 32 prospectively treated patients 125
Fertility-sparing surgery in epithelial ovarian cancer: A systematic review of oncological issues 125
Pre-chemotherapy hemoglobin levels and survival in patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen: Results of a multicenter retrospective Italian study 124
Optimal treatment of early-stage ovarian cancer 124
Optimizing treatment of the partially platinum-sensitive ovarian cancer patient 124
Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study 124
Overexpression of p185 is not related to erbB2 amplification in ovarian cancer 123
Fertility-Sparing Options in Young Women with Cervical Cancer 123
Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients 123
Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer 123
Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors 122
Defective natural killer activity within human ovarian tumors: Low numbers of morphologically defined effectors present in situ 122
Adult granulosa cell tumours of the ovary 122
A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis 121
Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities 121
Robotic Versus Open Radical Hysterectomy in Women With Locally Advanced Cervical Cancer After Neoadjuvant Chemotherapy: A Single-institution Experience of Surgical and Oncologic Outcomes 121
Multidisciplinary approach in the management of advanced ovarian cancer patients: A personalized approach. Results from a specialized ovarian cancer unit 121
Are monoclonal antibodies a safe treatment for cancer during pregnancy? 120
Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis 120
Management of ovarian stromal cell tumors 119
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval 119
Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships 119
A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma 119
Totale 14.441
Salva come PNG Salva come JPEG
Categoria #
all - tutte 134.476
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 134.476
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.863 0 0 0 588 626 812 879 501 655 260 422 120
2020/20214.780 335 227 446 451 535 396 481 511 396 478 199 325
2021/20223.002 181 245 348 237 184 196 168 209 186 250 231 567
2022/20234.033 665 1.028 274 226 247 729 59 327 243 66 95 74
2023/20244.164 98 105 176 111 637 1.033 755 107 525 117 68 432
2024/20253.026 713 1.688 492 133 0 0 0 0 0 0 0 0
Totale 34.056